Novartis AG v. Cipla Limited: Siponimod Patent Suit Voluntarily Dismissed
Novartis AG brought a three-patent infringement action against Cipla Limited in Delaware over generic siponimod tablets, asserting US11944602B2, US8492441B2, and US12071402B2. After 234 days, Novartis voluntarily dismissed all claims under Rule 41(a)(1)(A)(i), with each party bearing its own costs.
Novartis drops three-patent siponimod suit against Cipla in Delaware
On 14 February 2025, Novartis AG and Novartis Pharmaceuticals Corporation filed an infringement action against Cipla Limited in the Delaware District Court (Case No. 1:25-cv-00186), presided over by Judge John F. Murphy. The complaint asserted three patents — US11944602B2, US8492441B2, and US12071402B2 — each relating to siponimod, a sphingosine-1-phosphate receptor modulator marketed as Mayzent and approved for secondary progressive multiple sclerosis. The suit was triggered by Cipla’s efforts to bring a generic version of siponimod tablets to the US market.
On 6 October 2025, Novartis voluntarily dismissed all claims without prejudice pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i), which permits a plaintiff to dismiss before the defendant has served an answer or a motion for summary judgment. The notice stipulated that each party would bear its own attorneys’ fees and costs. Because the dismissal was without prejudice, Novartis retains the right to refile claims on the same patents against Cipla in the future, subject to applicable statutes of limitations and any future ANDA-related triggers.
The 234-day duration — resolved without substantive court rulings — is consistent with pre-answer voluntary dismissals that follow out-of-court negotiations, potential licensing discussions, or a reassessment of litigation strategy. The public record does not disclose whether a settlement, consent decree, or commercial agreement underlies the dismissal. The absence of any cost award to either party is typical for Rule 41(a)(1)(A)(i) dismissals, where the court has not been asked to exercise discretion over fee-shifting.
Filing to Voluntary dismissal in 234 days
234-day case duration — resolved before trial in the Delaware District Court
Voluntarily dismissed: what the Rule 41 exit means for both parties
Rule 41(a)(1)(A)(i): plaintiff’s unilateral right to exit
Federal Rule of Civil Procedure 41(a)(1)(A)(i) allows a plaintiff to dismiss an action without a court order before the defendant serves an answer or a motion for summary judgment. This is the earliest and most procedurally straightforward exit route. No merits ruling is made, and the patents are not adjudicated. The dismissal here was filed by Novartis alone, suggesting Cipla had not yet filed a formal responsive pleading.
No merits adjudicationWith or without prejudice? The record is silent
The verdict text states the dismissal was ‘without prejudice,’ meaning Novartis retains the right to refile these claims. A dismissal with prejudice would have permanently extinguished those claims. The practical difference is significant: without prejudice preserves Novartis’s enforcement options against Cipla on US11944602B2, US8492441B2, and US12071402B2, particularly if a new ANDA trigger or commercial launch event arises in the future.
Refiling rights preservedCipla faces no injunction — but risk is not extinguished
Cipla obtained no judgment invalidating or rendering unenforceable any of the three asserted patents. While the dismissal removes the immediate litigation threat, it does not clear the path to generic launch. Cipla’s ANDA for siponimod tablets remains subject to Novartis’s patent rights, and a refiled action — or a new suit following any attempted commercial launch — remains a realistic possibility given the without-prejudice nature of the exit.
No patent clearance for CiplaSiponimod generic entry remains legally uncertain
The voluntary dismissal without prejudice leaves the competitive landscape for generic siponimod unresolved. Novartis’s three patents — spanning formulation and method-of-use claims — remain issued and enforceable. Other generic filers in the siponimod space should treat this dismissal as a strategic pause, not a green light. The absence of a consent decree or court-approved settlement means there is no public record of any agreed launch date or licensing terms.
Patents remain enforceableFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Novartis, AG | Company | Pharmaceutical innovator and IP licensor — holder of US11944602B2, US8492441B2, US12071402B2Search in Eureka ↗ |
| Defendant | Cipla Limited | Individual | Indian generic pharmaceutical manufacturer seeking US market entry for siponimod tabletsSearch in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Joyce | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing Novartis, AGSearch in Eureka ↗ |
| Presiding judge | Judge John F. Murphy | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice invokes Rule 41(a)(1)(A)(i), confirming it was filed unilaterally by Novartis before Cipla served an answer. The ‘without prejudice’ designation is legally significant: it means no claim preclusion attaches and Novartis may reassert the same patents against Cipla. The mutual cost-bearing provision, while standard for early Rule 41 exits, is notable in Hatch-Waxman suits where fee-shifting under 35 U.S.C. § 285 is theoretically available. No court ever assessed the merits of the infringement or validity allegations.
US11944602B2, US8492441B2 & US12071402B2 — Siponimod formulation patents
The three asserted patents cover different layers of the siponimod product stack. US8492441B2 (application filed December 2009) represents the foundational formulation IP, likely covering the compound or core pharmaceutical composition. US11944602B2 and US12071402B2 — both with application dates in 2021 — suggest later-stage patent prosecution, consistent with Novartis’s strategy of extending exclusivity through formulation, method-of-use, or manufacturing improvements. Together, the portfolio creates a layered exclusivity structure that is characteristic of complex small-molecule CNS drugs.
Siponimod (Mayzent) is the first oral therapy approved specifically for secondary progressive multiple sclerosis, a market with significant unmet need and pricing power. Novartis’s decision to assert three patents — rather than relying on a single blocking patent — reflects the commercial importance of the product and the depth of its Hatch-Waxman filing strategy. The two 2021-application patents (US11944602B2 and US12071402B2) may carry patent terms extending well into the 2040s, making them particularly significant barriers for generic entrants seeking early market access.
Should you run an FTO against US11944602B2, US8492441B2 & US12071402B2?
Any company developing or formulating a generic or biosimilar version of siponimod — or a novel S1P receptor modulator with structural or functional similarity — should conduct a thorough freedom-to-operate analysis against all three patents. The without-prejudice dismissal in this case provides no safe harbour. The patents remain issued and enforceable, and Novartis has demonstrated willingness to litigate in Delaware.
PatSnap Eureka’s FTO Search Agent can map the claim scope of US11944602B2, US8492441B2, and US12071402B2 against your product formulation, identify prosecution history estoppel, and surface non-obviousness arguments used to obtain grant. This is particularly valuable for R&D teams working on S1P modulator formulations, modified-release siponimod, or next-generation MS oral therapies that may intersect with Novartis’s claim landscape.
Run a freedom-to-operate analysis on US11944602B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman siponimod and S1P modulator patent cases
Explore comparable Hatch-Waxman infringement actions in the Delaware District Court involving S1P receptor modulators and branded MS oral therapies.
What this case signals for the branded SPMS drug IP landscape
Three unresolved patents, a without-prejudice exit, and no public settlement — the siponimod exclusivity battle may not be over.
Without-prejudice dismissal preserves Novartis’s full enforcement arsenal
Novartis retains the right to refile on all three patents. Generic challengers and follow-on ANDA filers should not treat this dismissal as evidence of patent weakness. Monitoring for a refiled action — particularly around any attempted commercial launch by Cipla — is strongly advisable.
No cost award signals a negotiated or consensual exit, not a contested win
The mutual ‘own costs’ provision is consistent with a negotiated resolution rather than an adversarial dismissal. In Hatch-Waxman litigation, this pattern often precedes a confidential licensing or launch-date agreement, though none is disclosed here.
Novartis v Cipla — key questions answered
Novartis AG and Novartis Pharmaceuticals Corporation filed a three-patent infringement action against Cipla Limited in the Delaware District Court on 14 February 2025 over generic siponimod tablets. After 234 days, Novartis voluntarily dismissed all claims under Rule 41(a)(1)(A)(i), with each party bearing its own costs. No merits ruling was issued.
Novartis asserted three patents: US11944602B2 (application US17/209940), US8492441B2 (application US12/655049), and US12071402B2 (application US17/230175). All three relate to siponimod tablet formulations. US8492441B2 is the oldest, with a 2009 application date; the other two were filed in 2021.
A without-prejudice dismissal means Novartis’s claims were dropped without any finding on the merits, and Novartis retains the legal right to refile the same claims against Cipla in the future. The three asserted patents remain issued and enforceable. Cipla received no judgment clearing its path to generic launch.
No court ruling was made in favour of either party. The case was voluntarily dismissed by Novartis before Cipla even filed an answer. Cipla obtained no invalidity or non-infringement finding. The patents remain enforceable, and the without-prejudice dismissal means Novartis could refile. The outcome does not constitute a Cipla win on the merits.
Siponimod is a sphingosine-1-phosphate (S1P) receptor modulator sold by Novartis as Mayzent, approved for secondary progressive multiple sclerosis — the first oral therapy for that indication. Its commercial significance makes it a prime target for ANDA-based generic challenges. Novartis filed this suit in Delaware to assert its patent portfolio against Cipla’s generic ANDA, triggering the standard Hatch-Waxman 30-month stay mechanism.
PatSnap Eureka searches patents and litigation data to answer instantly.